Payment overview · 2025
General Payments
$104.11
6 reported records · 2 companies
Healthcare provider profile · identity verified
Michael P Wanger, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLEARWATER, FL · NPI 1437101359
Verified facts
What the public records show
CMS Open Payments records show Michael P Wanger, MD received $104.11 in general payments during 2025 across 6 reported records.
Amgen Inc. accounted for 77.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $80.90 | 77.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.21 | 22.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $104.11 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.33 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.33 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
214 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 742 | 195 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 660 | 202 |
| Atorvastatin Calcium | Atorvastatin Calcium | 640 | 188 |
| Amlodipine Besylate | Amlodipine Besylate | 500 | 144 |
| Lisinopril | Lisinopril | 438 | 128 |
| Losartan Potassium | Losartan Potassium | 436 | 128 |
| Simvastatin | Simvastatin | 314 | 83 |
| Alprazolam | Alprazolam | 303 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 267 | 81 |
| Metformin Hcl | Metformin Hcl | 259 | 85 |
| Omeprazole | Omeprazole | 239 | 69 |
| Eliquis | Apixaban | 214 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 65 |
| Potassium Chloride | Potassium Chloride | 183 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 49 |
| Allopurinol | Allopurinol | 158 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 40 |
| Glimepiride | Glimepiride | 122 | 32 |
| Furosemide | Furosemide | 118 | 42 |
| Atenolol | Atenolol | 113 | 32 |
| Trazodone Hcl | Trazodone Hcl | 111 | 30 |
| Prednisone | Prednisone | 107 | 63 |
| Alendronate Sodium | Alendronate Sodium | 106 | 37 |
| Lorazepam | Lorazepam | 99 | 17 |
| Gabapentin | Gabapentin | 93 | 30 |
| Tramadol Hcl | Tramadol Hcl | 92 | 42 |
| Methylprednisolone | Methylprednisolone | 90 | 75 |
| Sertraline Hcl | Sertraline Hcl | 90 | 27 |
| Carvedilol | Carvedilol | 89 | 22 |
| Ozempic | Semaglutide | 89 | 19 |
| Meloxicam | Meloxicam | 88 | 32 |
| Terazosin Hcl | Terazosin Hcl | 88 | 27 |
| Montelukast Sodium | Montelukast Sodium | 85 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 25 |
| Finasteride | Finasteride | 84 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 83 | 27 |
| Synthroid | Levothyroxine Sodium | 81 | 19 |
| Xarelto | Rivaroxaban | 80 | 19 |
| Celecoxib | Celecoxib | 74 | 29 |
| Nifedipine Er | Nifedipine | 73 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 35 |
| Ezetimibe | Ezetimibe | 65 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 18 |
| Donepezil Hcl | Donepezil Hcl | 61 | 16 |
| Spironolactone | Spironolactone | 60 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 49 |
| Farxiga | Dapagliflozin Propanediol | 57 | 18 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 23 |
| Irbesartan | Irbesartan | 52 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 16 |
| Azithromycin | Azithromycin | 46 | 37 |
| Jardiance | Empagliflozin | 46 | 11 |
| Famotidine | Famotidine | 45 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 29 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 13 |
| Temazepam | Temazepam | 40 | suppressed |
| Acyclovir | Acyclovir | 39 | 12 |
| Clonidine Hcl | Clonidine Hcl | 39 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 25 |
| Januvia | Sitagliptin Phosphate | 39 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Diazepam | Diazepam | 36 | 13 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Valsartan | Valsartan | 30 | 11 |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | 11 |
| Rybelsus | Semaglutide | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Dexamethasone | Dexamethasone | 17 | 16 |
| Famciclovir | Famciclovir | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Dexilant | Dexlansoprazole | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Itraconazole | Itraconazole | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $104.11 · 6 records | Amgen Inc. | EVENITY, NURTEC ODT, OTEZLA, REPATHA, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error